FDA Dropped TRT’s Heart Warning: What Cops Should Know

If you’ve ever brought up testosterone with a department doc or a skeptical PCP, you’ve probably heard some version of “that stuff causes heart attacks.” As of 2025, the label they were pointing at doesn’t say that anymore. But the same trial that got the warning pulled also turned up three findings nobody is putting on a clinic billboard — and two of them matter a lot if you carry a badge or ride a rig.

What the FDA Actually Changed

In late February 2025, the FDA ordered a class-wide labeling change across every testosterone product on the market. Three things happened at once:

• The Boxed Warning language about increased risk of adverse cardiovascular outcomes was removed.
• Results from the TRAVERSE trial were added to every product’s label.
• A new warning about increased blood pressure was added — with ambulatory blood pressure monitoring data included for products that had completed those studies.

That’s not the FDA declaring testosterone heart-healthy. It’s the FDA saying the old warning wasn’t supported by the best available trial, and swapping it for a narrower, better-evidenced one.

TRAVERSE was a phase 4 trial of roughly 5,200 men aged 45 to 80 with hypogonadism who were at high cardiovascular risk to begin with — meaning it was deliberately stacked with the guys most likely to have an event. Over the study period, men on testosterone had a similar rate of cardiovascular death, nonfatal heart attack, and nonfatal stroke compared to men on placebo. For a population that already had heart disease or multiple risk factors, that’s a meaningful non-finding.

The Three Things That Went the Other Way

Here’s the part your telehealth clinic’s marketing email skipped. Three adverse events showed up more often in the testosterone group:

1. Atrial fibrillation — about 3.5% on testosterone versus about 2.4% on placebo.
2. Pulmonary embolism — roughly 0.9% versus 0.5%.
3. Acute kidney injury — roughly 2.3% versus 1.5%.

And in the fracture arm of the trial, published separately, testosterone did not reduce clinical fractures — the rate was actually numerically higher in the treatment group, with a hazard ratio around 1.4. That surprised researchers, since testosterone improves bone density. Density and fracture resistance apparently aren’t the same thing.

Then there’s blood pressure. In TRAVERSE, mean systolic pressure ticked up slightly in the testosterone group while the placebo group’s drifted down. It’s a small average difference — but averages hide individuals, and some men on testosterone see a real, sustained climb.

Why This Matters More for First Responders

Take those four signals and lay them over the job.

Atrial fibrillation is a fitness-for-duty problem, not just a health problem. Depending on your department and how it reads NFPA 1582, new-onset a-fib can trigger a medical evaluation, an anticoagulation decision, and a hard conversation about interior firefighting or pursuit driving. Shift work and heavy alcohol use — both overrepresented in public safety — already raise a-fib risk. Testosterone stacks onto that, it doesn’t replace it.

Blood pressure is the one that will actually get you. First responders already run high — the combination of circadian disruption, adrenaline spikes, sodium-heavy station food, and untreated sleep apnea is close to a purpose-built hypertension machine. If your resting pressure was 138/86 before you started TRT, a few more points is not a rounding error. It’s the difference between “monitored” and “medicated.”

Kidney injury risk gets amplified by the heat stress and dehydration that come standard on the fireground, and by the NSAIDs a lot of guys eat like candy for chronic back and shoulder pain.

Fractures matter because a lot of the pitch for testosterone in your 40s and 50s is “stay durable.” The bone-density number improves. The trial says the fracture outcome didn’t.

What to Actually Do About It

If you’re on TRT or considering it, this is the monitoring floor — and it’s more than most direct-to-consumer clinics will run on their own:

1. Cuff at home, not just at the doc. Get a validated upper-arm monitor. Take readings at the same point in your shift cycle, twice a week, for four weeks before starting and for the first three months after. Bring the log.
2. Get a baseline EKG if you have any history of palpitations, a family history of a-fib, or heavy alcohol use. You want a comparison tracing on file before symptoms show up at 0300.
3. Watch hematocrit every 3–6 months. Elevated hematocrit is the plausible mechanism behind the clotting signal. If it climbs past your provider’s threshold, dose reduction or a schedule change usually beats therapeutic phlebotomy as a first move.
4. Run a basic metabolic panel with eGFR at baseline and annually — more often if you work heavy fire duty or take NSAIDs regularly.
5. Ask about dose and frequency. Smaller, more frequent injections generally produce flatter levels and less hematocrit drift than a big weekly or biweekly bolus.
6. Treat the sleep apnea first. If you’re undiagnosed and snoring, testosterone can worsen it — and untreated apnea drives both the blood pressure and the a-fib risk independently.

The Honest Read

The boxed warning came off because the evidence didn’t support it. That’s a win for anyone who’s had a provider refuse to treat clearly symptomatic low testosterone out of medicolegal fear. But “not a heart attack risk” isn’t the same as “no cardiovascular considerations at all,” and a clinic that tells you the FDA cleared testosterone without mentioning the blood pressure warning is selling, not informing.

You already run toward the thing everyone else runs from. You can handle the full picture. Ask your provider — or the clinic you’re evaluating — whether they monitor blood pressure and hematocrit on a schedule, or whether they just refill the vial. The answer tells you what kind of care you’re buying.

For more first responder–specific reviews and comparisons on TRT providers, labs, and monitoring, visit policefire.health.

This article is for informational purposes only and does not constitute medical advice. BadgeBiohacking (policefire.health) is a comparison and review site. We may earn affiliate commissions from links on this site. Always consult a qualified healthcare provider before starting any treatment.